Managing hepatitis C in liver transplant patients with recurrent infection

摘要: Hepatitis C virus (HCV) reinfection after liver transplantation (LT) and recurrent hepatitis often lead to cirrhosis (RC). RC is one of the most frequent complications resulting in organ failure early death LT HCV-positive patients with reported 5-year rates from 20% 40%. As HCV-cirrhosis leading indications for LT, therapeutic management a central issue. To date, best available therapy combination pegylated interferon + ribavirin established proven by biopsy. Although increasing experience using has suggested better response rates, treatment limited poor tolerability high severe side effects, necessitating lower doses or withdrawal therapy. The extent which dose reductions concomitant administration growth factors affect virological prevent still be determined. Prospective clinical trials are mandatory identify time point schedule antiviral transplant patients. Currently, options need discussed each individual patient. Therefore should carried out only centers managing LT.